All Articles

Alto Neuroscience Wants To Be The Next Big Biotech IPO

January 15, 2024
x min read

One of the most exciting drug developers in neuroscience is getting ready for their Wall Street debut.

What’s happening:

  • Los Altos, California based biotech company Alto Neuroscience has officially filed with the SEC to raise $100M USD in an IPO on the New York Stock Exchange

The big idea:

  • Alto leverages artificial intelligence to analyze biomarkers in patients to be able to precisely determine which therapeutics will be most effective for them
  • By focusing on discovering highly specific biomarkers, Alto is also able to identify subtypes of diseases which are not easily found through traditional clinical screening
  • Alto then takes this data and uses it to develop novel therapeutics they believe will be highly impactful for mental health conditions and brain disorders

Why it matters:

Going deeper:

  • Alto Neuroscience already has a number of notable investors including Christian Angermayer’s Apeiron Group, Steve Cohen’s Point72, Eli Lily, Franklin Templeton and more
  • Alto's most advanced novel drugs are currently in Phase IIb trials focused on Major Depressive Disorder

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.